Recent chatter on X about Amgen (AMGN) has been buzzing with interest following the company's announcement of a $2.38 dividend per share for Q3 2025 and successful Phase 3 clinical trial results. Many users are pointing to these developments as potential catalysts for renewed investor confidence, especially amid a 5.6% price increase over the last quarter. The discussion often highlights optimism around the stock's future trajectory based on these updates.
However, not all sentiments are uniformly positive, as some conversations on X also reflect concerns over recent price declines and broader market volatility affecting Amgen. Technical indicators and price movements are frequently debated, with a mix of bullish signals from earlier uptrends and caution over short-term dips noted in posts. This blend of perspectives keeps the dialogue dynamic and engaging for those tracking the biotech giant.
Note: This discussion summary was generated from an AI condensation of post data.
Amgen Congressional Stock Trading
Members of Congress have traded $AMGN stock 11 times in the past 6 months. Of those trades, 8 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $AMGN stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN purchased up to $15,000 on 06/24.
- REPRESENTATIVE CLIFF BENTZ purchased up to $15,000 on 06/06.
- REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 2 times. They made 2 purchases worth up to $30,000 on 05/14, 05/05 and 0 sales.
- REPRESENTATIVE JEFFERSON SHREVE has traded it 3 times. They made 2 purchases worth up to $100,000 on 04/11, 02/24 and 1 sale worth up to $50,000 on 05/12.
- REPRESENTATIVE JARED MOSKOWITZ has traded it 2 times. They made 2 purchases worth up to $30,000 on 04/16 and 0 sales.
- SENATOR TOMMY TUBERVILLE sold up to $50,000 on 04/15.
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $15,000 on 04/08.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Amgen Insider Trading Activity
Amgen insiders have traded $AMGN stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $AMGN stock by insiders over the last 6 months:
- RACHNA KHOSLA (SVP, Business Development) sold 1,500 shares for an estimated $434,520
- NANCY A. GRYGIEL (SVP & CCO) sold 1,267 shares for an estimated $376,279
- MATTHEW C. BUSCH (VP, Finance & CAO) sold 1,000 shares for an estimated $279,690
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Amgen Hedge Fund Activity
We have seen 1,342 institutional investors add shares of Amgen stock to their portfolio, and 1,387 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS added 3,775,911 shares (+24.9%) to their portfolio in Q2 2025, for an estimated $1,054,272,110
- GAMMA INVESTING LLC removed 3,649,816 shares (-99.7%) from their portfolio in Q2 2025, for an estimated $1,019,065,125
- PRIMECAP MANAGEMENT CO/CA/ removed 1,756,586 shares (-14.2%) from their portfolio in Q2 2025, for an estimated $490,456,377
- BLACKROCK, INC. added 1,158,907 shares (+2.6%) to their portfolio in Q2 2025, for an estimated $323,578,423
- TWO SIGMA ADVISERS, LP removed 997,300 shares (-99.6%) from their portfolio in Q2 2025, for an estimated $278,456,133
- PRICE T ROWE ASSOCIATES INC /MD/ removed 895,054 shares (-43.9%) from their portfolio in Q2 2025, for an estimated $249,908,027
- VANGUARD GROUP INC added 841,117 shares (+1.6%) to their portfolio in Q2 2025, for an estimated $234,848,277
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Amgen Analyst Ratings
Wall Street analysts have issued reports on $AMGN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Underperform" rating on 07/23/2025
- Piper Sandler issued a "Overweight" rating on 06/27/2025
- RBC Capital issued a "Outperform" rating on 05/02/2025
To track analyst ratings and price targets for Amgen, check out Quiver Quantitative's $AMGN forecast page.
Amgen Price Targets
Multiple analysts have issued price targets for $AMGN recently. We have seen 10 analysts offer price targets for $AMGN in the last 6 months, with a median target of $313.5.
Here are some recent targets:
- Trung Huynh from UBS set a target price of $317.0 on 08/06/2025
- Terence Flynn from Morgan Stanley set a target price of $333.0 on 08/06/2025
- Geoff Meacham from Citigroup set a target price of $310.0 on 08/06/2025
- Tim Anderson from B of A Securities set a target price of $261.0 on 07/23/2025
- David Amsellem from Piper Sandler set a target price of $328.0 on 06/27/2025
- Carter Gould from Cantor Fitzgerald set a target price of $305.0 on 06/24/2025
- Vamil Divan from Guggenheim set a target price of $288.0 on 05/20/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
